FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease

July 3, 2024 - By admin

Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.